PE-backed New England Peptide appoints CEO and CFO

New England Peptide, which is backed by Ampersand Capital Partners, has named Dr. Martina Diekmann as CEO and David Gavlik as chief financial officer.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this